Acquisition Opportunity RMI was acquired by Senzime for 44M in early 2022, suggesting potential continuity in product integration or cross-selling opportunities with Senzime’s existing customer base and distribution channels.

High Growth ARPU Current revenue range of 1–10 million and a funded total of 34 million indicate a scalable medical device with room to expand sales through hospital systems, distributors, and international markets leveraging ExSpiron’s noninvasive continuous respiratory monitoring.

Strategic Fit ExSpiron’s capability to display lung volumes and provide MV, TV, and RR for non-intubated patients aligns with demand for continuous monitoring to improve patient safety and reduce cost of care, presenting cross-sell potential to hospitals expanding respiratory care programs.

Key Relationships Leadership and board activity, including hires and board appointments, indicate a governance framework supportive of partnerships; engage with their executives and board members to explore co-development, distribution, or licensing opportunities.

Market Expansion With FDA clearance and CE Mark and a positioning as a global leader in minute ventilation monitoring, focus on expanding into new care settings (ICUs, post-acute, telemedicine) and geographies where continuous MV monitoring is increasingly valued.